HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T-DM1).

source https://medicalxpress.com/news/2021-09-her2-targeting-antibody-drug-progression-free-survival-women.html